Literature DB >> 31285946

Pivotal role of microRNA-138 in human cancers.

Margaret Yeh1, Christina S Oh2, Ji Young Yoo1, Balveen Kaur1, Tae Jin Lee1.   

Abstract

Aberrant expression of certain microRNAs (miRNAs) has been implicated in cancers as a promising druggable target due to the fact that a modulation of the deregulated single miRNA seems to revert the therapeutically unfavorable gene expressions in cancer cell by targeting multiple genes. Global miRNA profiling from a number of patient cohorts in various type of human cancers has identified miR-138 as a signature of tumor suppressor that are down-regulated in most types of human cancer. As a tumor suppressor, miR-138 can inhibit oncogenic proteins by directly bind to their mRNAs. However, in rare cases of cancer stem cell population from glioblastoma, miR-138 seems to be down-regulated and plays an oncogenic function. This review will summarize accumulating evidence that has shown the expression and functional role of miR-138 in various human cancers with its target genes and pathways in a hope to find a better therapeutic option to treat human cancers.

Entities:  

Keywords:  MicroRNA; cancer; glioblastoma; miR-138; oncogene; tumor suppressor

Year:  2019        PMID: 31285946      PMCID: PMC6610051     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  21 in total

1.  Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells.

Authors:  Ravneet Chhabra; Stephanie Rockfield; Jennifer Guergues; Owen W Nadeau; Robert Hill; Stanley M Stevens; Meera Nanjundan
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

2.  The role of miR-370 and miR-138 in the regulation of BMP2 suppressor gene expression in colorectal cancer: preliminary studies.

Authors:  Agnieszka Piechowska; Celina Kruszniewska-Rajs; Magdalena Kimsa-Dudek; Magdalena Kołomańska; Barbara Strzałka-Mrozik; Joanna Gola; Stanisław Głuszek
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-15       Impact factor: 4.553

Review 3.  Emerging Epigenetic Therapies for Brain Tumors.

Authors:  Lokesh Kukreja; Catherine J Li; Sathyapriya Ezhilan; Vishwanath R Iyer; John S Kuo
Journal:  Neuromolecular Med       Date:  2021-10-22       Impact factor: 3.843

4.  Linking miR-138 and USP10-P53 signaling.

Authors:  Ri Cui
Journal:  Oncotarget       Date:  2019-11-12

5.  Astragalus Polysaccharides Inhibits Tumorigenesis and Lipid Metabolism Through miR-138-5p/SIRT1/SREBP1 Pathway in Prostate Cancer.

Authors:  Shanqi Guo; Baojie Ma; Xingkang Jiang; Xiaojiang Li; Yingjie Jia
Journal:  Front Pharmacol       Date:  2020-05-05       Impact factor: 5.810

6.  Analysis of miR-9-5p, miR-124-3p, miR-21-5p, miR-138-5p, and miR-1-3p in Glioblastoma Cell Lines and Extracellular Vesicles.

Authors:  Alja Zottel; Neja Šamec; Ana Kump; Lucija Raspor Raspor Dall'Olio; Pia Pužar Dominkuš; Rok Romih; Samo Hudoklin; Jernej Mlakar; Daniil Nikitin; Maxim Sorokin; Anton Buzdin; Ivana Jovčevska; Radovan Komel
Journal:  Int J Mol Sci       Date:  2020-11-11       Impact factor: 5.923

7.  miR‑592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin‑dependent kinase 8.

Authors:  Ting Liu; Jingjing Meng; Yu Zhang
Journal:  Mol Med Rep       Date:  2020-07-30       Impact factor: 2.952

8.  Transplantation of bone marrow-derived mesenchymal stem cells with silencing of microRNA-138 relieves pelvic organ prolapse through the FBLN5/IL-1β/elastin pathway.

Authors:  Bing Zhao; Qing Sun; Yazhou Fan; Xinming Hu; Linyu Li; Junmin Wang; Shihong Cui
Journal:  Aging (Albany NY)       Date:  2021-01-16       Impact factor: 5.682

Review 9.  MicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer.

Authors:  Eunsun Jung; Jinhyeon Choi; Jang-Seong Kim; Tae-Su Han
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-08

10.  MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44.

Authors:  Margaret Yeh; Yin-Ying Wang; Ji Young Yoo; Christina Oh; Yoshihiro Otani; Jin Muk Kang; Eun S Park; Eunhee Kim; Sangwoon Chung; Young-Jun Jeon; George A Calin; Balveen Kaur; Zhongming Zhao; Tae Jin Lee
Journal:  Sci Rep       Date:  2021-04-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.